Thermo Fisher Scientific Additional Paid-In Capital increased by 1.3% to $18.56B in Q4 2025 compared to the prior quarter. Year-over-year, this metric grew by 3.3%, from $17.96B to $18.56B. Over 5 years (FY 2020 to FY 2025), Additional Paid-In Capital shows an upward trend with a 3.6% CAGR.
An increase typically signals recent equity financing activities or the issuance of shares for employee compensation.
Additional paid-in capital represents the amount of capital received from investors in excess of the par value of the is...
Common in all corporations; levels depend on the history of equity issuance and stock-based compensation.
additional_paid_in_capital| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $15.83B | $15.96B | $16.17B | $16.29B | $16.47B | $16.60B | $16.74B | $16.89B | $17.03B | $17.17B | $17.29B | $17.48B | $17.65B | $17.83B | $17.96B | $18.11B | $18.23B | $18.33B | $18.56B |
| QoQ Change | — | +0.8% | +1.3% | +0.7% | +1.1% | +0.8% | +0.9% | +0.9% | +0.8% | +0.8% | +0.7% | +1.1% | +1.0% | +1.0% | +0.7% | +0.8% | +0.7% | +0.5% | +1.3% |
| YoY Change | — | — | — | — | +4.1% | +4.0% | +3.5% | +3.7% | +3.4% | +3.4% | +3.2% | +3.5% | +3.6% | +3.9% | +3.9% | +3.6% | +3.3% | +2.8% | +3.3% |
We use cookies for analytics. See our Privacy and Cookie Policy.